{"id":116673,"date":"2022-05-05T14:54:00","date_gmt":"2022-05-05T11:00:00","guid":{"rendered":"https:\/\/hispanicprwire.com\/english-innova-medical-group-forms-strategic-partnership-with-attomarker-to-accelerate-covid-immunity-testing\/"},"modified":"2022-05-05T15:00:04","modified_gmt":"2022-05-05T19:00:04","slug":"innova-medical-group-forma-una-alianza-estrategica-con-attomarker-para-acelerar-las-pruebas-de-inmunidad-a-la-covid","status":"publish","type":"post","link":"https:\/\/hispanicprwire.com\/en\/innova-medical-group-forma-una-alianza-estrategica-con-attomarker-para-acelerar-las-pruebas-de-inmunidad-a-la-covid\/","title":{"rendered":"Innova Medical Group Forms Strategic Partnership with Attomarker to Accelerate COVID Immunity Testing"},"content":{"rendered":"<p><\/p>\n<style type=\"text\/css\"><![CDATA[\n\/* Style Definitions *\/\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n]]><\/style>\n<div class=\"xn-content\">\n<p><span class=\"xn-location\">PASADENA, Calif.<\/span>, <span class=\"xn-chron\">May 5, 2022<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; Innova Medical Group, Inc., a global health screening and diagnostic innovator and a world leader in the manufacturing and distribution of COVID-19 rapid tests, along with Attomarker, a nanophotonic biochemical testing company spun from the University of <span class=\"xn-location\">Exeter<\/span> in the United Kingdom,\u00a0announced today that the two companies have formed a strategic partnership to expedite immunity testing for COVID and other diseases globally.<\/p>\n<div id=\"prni_dvprnejpg990eleft\" dir=\"ltr\" style=\"width: 100%; text-align: left;\"><img decoding=\"async\" id=\"prnejpg9f66left\" title=\"Innova Medical Group Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/1494814\/Innova_tagline_blue_Logo.jpg\" alt=\"Innova Medical Group Logo\" align=\"middle\"\/><\/div>\n<p>Attomarker&#8217;s CE marked and UK Medicines and Healthcare products Regulatory Agency (MHRA) accredited rapid COVID Antibody Immunity Test assesses an individual&#8217;s antibody levels and estimates when they will likely be on the edge of immunity; providing vital insight for patients and public health officials to better inform the timing of vaccine shots and other protective measures.<\/p>\n<p>The device is the first of its kind to measure an individual&#8217;s immune response to a COVID-19 vaccination, booster, infection \u2013 or a combination of the immune triggers and is currently available in clinics in the UK and the <span class=\"xn-location\">Caribbean<\/span>.<\/p>\n<p>As part of the partnership, Innova Medical Group made a minority investment in Attomarker and will become an official distributor of its products. Innova&#8217;s commercial capability in the rapid test space will help stimulate the development of Attomarker&#8217;s unique, multiplexed platform technology to achieve advances in rapid point-of-care diagnostics and personalized medicine.<\/p>\n<p>&#8220;We are excited about working with the Attomarker team to help them accelerate growth,&#8221; said <span class=\"xn-person\">Daniel Elliott<\/span>, CEO of Innova Medical Group. &#8220;Adding a much-needed immunity test into Innova&#8217;s COVID rapid test portfolio strengthens the pandemic management solution we offer to our global customers.&#8221;\u00a0<\/p>\n<p>Attomarker&#8217;s immunity testing technology\u00a0measures multiple biomarkers in blood and saliva to provide a personal profile for up to 20 tests in seven minutes. Forthcoming tests include biomarkers for liver health, food allergies and fertility.\u00a0<\/p>\n<p>&#8220;Attomarker&#8217;s technology has the potential to change healthcare diagnosis and treatment with a portfolio of near-patient rapid diagnostics that would lead to more effective clinical intervention,&#8221; added <span class=\"xn-person\">Todd Malan<\/span>, MD, Chief Medical Officer of Innova. &#8220;Most immediately, as protection from previous COVID infections and vaccinations decline and boosters continue to roll out, Attomarker&#8217;s science-based COVID-19 Antibody Immunity Test will be a valuable tool for individuals to make science based personalized healthcare decisions.&#8221;<\/p>\n<p>Professor <span class=\"xn-person\">Andrew Shaw<\/span>, CEO and founder of Attomarker said,\u00a0&#8220;This strategic alliance with Innova delivers a big boost to the Attomarker vision to a truly global perspective. We look forward to bringing more rapid solutions to help clinicians optimize interventions and enable people to take greater control over their own health.&#8221; \u00a0<\/p>\n<p><b>About Innova Medical Group<br \/><\/b>Innova Medical Group is a global health screening and diagnostic innovator driven to dramatically improve health outcomes worldwide with equitable, high-value testing solutions. Our strategic and iterative approach enables us to create, build and deploy myriad accessible tests customized to meet and empower the user at their point of need.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3526364-1&amp;h=3267305896&amp;u=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.innovamedgroup.com%252F%26data%3D04%257C01%257Cjosie.zheng%2540innovamedgroup.com%257Ca3292f30b77f42fb266108da1bd8bad4%257C18986c76406a4a8096804e356f4cea8c%257C0%257C0%257C637852914918151785%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C3000%26sdata%3D1zBX74%252BhtJhB1WyBW9ORospz3zaBXdgTBbEQk0U1%252Fv8%253D%26reserved%3D0&amp;a=www.innovamedgroup.com\" target=\"_blank\" rel=\"nofollow\">www.innovamedgroup.com<\/a><\/p>\n<p><b>About Attomarker Ltd<br \/><\/b>Attomarker Ltd is a MedTech company which was formed as a result of ground-breaking work conducted by Professor <span class=\"xn-person\">Andrew Shaw<\/span> and his research group at the University of <span class=\"xn-location\">Exeter<\/span>. The Attomarker vision is to personalise diagnostics and medicine\u00a0by creating the world&#8217;s best, most efficient, affordable and sustainable diagnostics platforms for near patient, home testing and mail away use. Attomarker offers a\u00a0complete rapid near-patient diagnostics system and has an exciting product pipeline. <a href=\"http:\/\/www.attomarker.com\" rel=\"nofollow\">www.attomarker.com<\/a><\/p>\n<p>Logo &#8211; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3526364-1&amp;h=1253596495&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1494814%2FInnova_tagline_blue_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1494814%2FInnova_tagline_blue_Logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/1494814\/Innova_tagline_blue_Logo.jpg<\/a><\/p>\n<p>SOURCE  Innova Medical Group, Inc.<\/p>\n<\/div>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<div class=\"xn-content\">\n<p><span class=\"xn-location\">PASADENA, Calif.<\/span>, <span class=\"xn-chron\">May 5, 2022<\/span> \/PRNewswire-HISPANIC PR WIRE\/ &#8212; Innova Medical Group, Inc., a global health screening and diagnostic innovator and a world leader in the manufacturing and distribution of COVID-19 rapid tests, along with Attomarker, a nanophotonic biochemical testing company spun from the University of <span class=\"xn-location\">Exeter<\/span> in the United Kingdom,\u00a0announced today that the two companies have formed a strategic partnership to expedite immunity testing for COVID and other&#8230;<\/p>\n","protected":false},"author":1,"featured_media":116674,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-116673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-salud"],"acf":[],"_links":{"self":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/116673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/comments?post=116673"}],"version-history":[{"count":"1","href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/116673\/revisions"}],"predecessor-version":[{"id":116687,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/posts\/116673\/revisions\/116687"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media\/116674"}],"wp:attachment":[{"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/media?parent=116673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/categories?post=116673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hispanicprwire.com\/en\/wp-json\/wp\/v2\/tags?post=116673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}